8 Acquisition International - Global Green Business Awards 2021 Best Biotechnology Platform - Asia n enzyme is a biocatalyst, which means it is an engine of the cell. In simpler terms, flowers give off aromas, and fruit develops a taste due to enzymes working together to convert nutrition to the scent or taste of an item. Currently, there are over 75,000 different variations of enzymes within the human body, and Allozymes aims to engineer these enzymes to replace natural extracts or artificial ingredients that come from oil without disrupting nature or utilising vast resources. Founded only two years ago, Allozymes has engineered breakthrough products utilising highly regarded research and studies towards developing the next generation of enzyme engineering platforms. As a result, Allozyme platforms can build and test millions of enzymes per day, which aids in the development of building effective enzymes by 200%. Additionally, by increasing the speed of development and probability of success, the company has been able to accelerate innovative product introduction and launch timely into the market up to 10 times faster than that compared to robotics technology. Thus, its breakthrough development in synthetic biology has enabled significant progress towards various industries. “At Allozymes, we are applying our proprietary microfluidics technology to screen 10M enzymes variants per day to develop custom-designed enzymes for cleaner and sustainable manufacturing of complex natural products,” explains Co-Founder and CEO Peyman Salehian. Allozymes has been working on several exclusive projects, including the biosynthesis of low yield tomato natural extracts for the cosmetic industry, the biosynthesis of lamb taste for vegan plant-based lamb meat, engineering enzymes for degrading plastic waste, and creating supremely efficient enzymes for home care products. Part of what makes Allozymes incredibly unique within the industry is how it differentiates itself from its competitors. With technology enabling the company to engineer faster and with a high success rate compared to other competitive enzyme engineering contracted organisations, Allozymes is able to lower market time for its A Recognised as Asia’s Best Biotechnology Platform, Allozymes aims to be ‘the google of enzymes,’ a place where you can discover and engineer enzymes for various sustainable manufacturing needs. Providing custom-designed enzymes, Allozymes is the fastest experimental enzyme engineering platform globally, with plans to accelerate the biotransformation within the synthetic biology industry. Currently, with Allozymes commercialised technology, it is able to address the $600B market with a pipeline of projects worth millions and products worth billions. Company: Allozymes Pte Ltd Name: Peyman Salehian Email: Peyman@allozymes.com Web Address: www.allozymes.com Nov21620 customers and offer affordable projects that service more customers over time and with greater flexibility. Additionally, Allozymes generations up to 10M data sets per day to continue its vision of creating the most extensive enzyme data library across the glove, thus, competing against computational enzyme design companies. “Our synthetic biology approach is different than strain developers because we are an enzyme engineering company with a capacity to optimise the strain at the same time,” explains Peyman. Allozymes focuses on cleaner and sustainable manufacturing of complex natural products, thus, putting an end to extractions that cost a significant amount of water, nutrition and land. Instead, the company is able to recreate enzymes by placing them in its bioreactor to produce extracts that do not harm the original and primary focus and at a more negligible resource cost. The company firmly believes in the change of biotechnology, and it all starts with the importance of its data library. The library is upheld by a strong emphasis that its benefits could significantly impact several industries for sustainable manufacturing. Going even further, Allozymes dramatically plans to change how enzymes are found in the first place. “Currently at Allozyme, we are engineering and transforming enzymes- taking it and finding ways to make it more efficient as well as how these enzymes are discovered. By doing so, we are accumulating a huge amount of data through engineering which can be used to build a massive library of enzymes, which will likely be available in three years,” explains Peyman. The use of this library will allow companies in future to ‘google’ precisely what they are looking for within Allozymes data sets instead of having to disrupt nature to find them. Aground-breaking introduction for the biotransformation industry that started a little over two years ago – a massive achievement in the ways of synthetic biology, all thanks to Allozymes. At Allozyme, the first year was about establishment and impressions, and with the years to come, the company aims to expand and continue innovation with the use of its unparalleled
RkJQdWJsaXNoZXIy NTY1MjI4